PACE-CME

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Investigational epigenetic therapy lowers incidence of MACE in phase b study
RestartResume
3' education - Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
  • Overview

    AHA 2016 The orally active epigenetic drug RVX-208 or apabetalone that alters gene activity by modifying chromatin structure, lowered the incidence of MACE in a phase 2b study. This effect could not entirely be attributed to an effect on HDL, explains dr. Norman Wong.

  • Educational information

    AHA 2016 The orally active epigenetic drug RVX-208 or apabetalone that alters gene activity by modifying chromatin structure, lowered the incidence of MACE in a phase 2b study. This effect could not entirely be attributed to an effect on HDL, explains dr. Norman Wong, and varous analyses give insight into other processes that seem beneficially affected.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free